System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Thomas Vanwolleghem is an expert in Hepatology at Antwerp University Hospital (Belgium). Thomas Vanwolleghem has authored 191 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 4 of them ongoing. SLR score: 976 (community average: 125). How the SLR is computed.

LeadR Profile

Thomas Vanwolleghem Antwerp University Hospital Belgium
976 ScienceLeadR Reputation 976

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2007 - 2026
Source: PubMed

Antwerp University Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 191

Citations

Citations: 5 365 1st author: 12 Last author: 51 Unique author: 0

Main journals

J Hepatol 71
Acta Gastroenterol Belg 8
Hepatology 8
J Viral Hepat 6
J Virol 5

Best Journals

J Hepatol 22
Lancet Gastroenterol Hepatol 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Immune Control, HBsAg Loss or Flare Requiring Liver Transplant-Diverse Outcomes After Stopping NUC Therapy.
PMID 42797857 — hepatitis b surface antigens, liver transplantation, serum, virology, liver, transplants, therapeutics, hepatitis, prospective studies		Viruses20260
Viral hepatitis among vulnerable migrant and refugee populations in Europe - an expert perspective from the Viral Hepatitis Prevention Board.
PMID 42723724 — public health, therapeutics, hepatitis		Wellcome Open Res20260
Detection of Infectious Hepatitis E Virus in Retail Pork Pâté After Optimization of Extraction Protocols.
PMID 42515612 — hepatitis e virus, virology, meat, food, viruses, hepatitis a, hepatitis e, hepatitis		Viruses20260
What lies beneath? Hepatitis E virus surveillance in Belgian wastewater suggests hidden trends in community circulation.
PMID 42480405 — hepatitis e virus, viruses, genotype, hepatitis e, research, complement system proteins, environment, infections, hepatitis		Sci Total Environ20260
Hepatic venous pressure gradient, non-invasive tests, and prognosis across the subtypes of advanced steatotic liver disease.
PMID 42276315 — liver diseases, hypertension, mortality, non-alcoholic fatty liver disease, venous pressure, liver, hypertension, portal, prognosis		Clin Gastroenterol Hepatol20260

Clinical Studies 16

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 1

By phase:

N/A 6
Phase 2 4
Phase 4 3
Phase 1 2
Phase 3 1

By status:

Completed 6
Recruiting 5
Terminated 2
Unknown 2
Active not recruiting 1

By type:

Interventional 11
Observational 5

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 2
multicentricup10 10

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Efficacy and safety of vamifeport in adult subjects with HFE related hereditary hemochromatosis
2025-523793-16-00 — genes, safety, double-blind method, hemochromatosis, genes, regulator		Phase 2Recruiting2026
The PEARL trial Prevention of hepatic Encephalopathy by administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt a multi centre randomized double blind placebo controlled trial
2024-512040-28-01 — liver cirrhosis, multiple chronic conditions, liver, alcoholics, liver cirrhosis, alcoholic, portasystemic shunt, surgical, lactulose, brain diseases, diagnosis, rifaximin, hepatic encephalopathy		Phase 4Recruiting2026
Muscle Mass Via UltraSound in Cirrhosis (MMUSCLE)
NCT06345547 — research design, muscles, malnutrition, fibrosis, prevalence, muscle, skeletal, hand strength, sarcopenia		N/ARecruiting2024
COIN B COntrolled Interruption of Nucleos(t)Ide Analogue Treatment in Chronic Hepatitis B Infections
NCT04779970 — hepatitis, chronic, hepatitis a, therapeutics, hepatitis b, hepatitis b, chronic, infections, hepatitis		N/AActive not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS